T-cell receptor and costimulatory molecules (TCR/Costimulators)

T-cell receptors (TCRs) and costimulatory molecules are the primary drivers of T-lymphocyte activation and the subsequent adaptive immune response. The TCR complex is responsible for the specific recognition of peptide antigens presented by major histocompatibility complex (MHC) molecules, a process known as Signal 1 [1]. However, TCR engagement alone is often insufficient for full activation and can lead to anergy without a secondary signal, known as Signal 2, provided by costimulatory molecules [2]. The most well-characterized costimulatory interaction is between CD28 on T-cells and CD80/CD86 on antigen-presenting cells [3]. In oncology, therapeutic agents like checkpoint inhibitors target these pathways to overcome tumor-induced immunosuppression, while in autoimmunity, drugs like abatacept inhibit costimulation to dampen self-reactive T-cell activity [4]. Furthermore, modern adoptive cell therapies, such as CAR-T cells, integrate costimulatory domains (e.g., 4-1BB or CD28) directly into the synthetic receptor to enhance the persistence and potency of the engineered cells against cancer [5]. Understanding the balance between these activating and inhibitory signals is crucial for developing targeted immunotherapies across a wide range of human diseases [6]. Citations: [1] UniProt (P04234); [2] StatPearls, T-Cell Antigen Receptors; [3] PubMed (PMID: 24011561); [4] PubChem (Abatacept); [5] NIH, CAR T Cells; [6] Nature Reviews Immunology (PMID: 23907114).

Other names

TCR complexT-cell activation moleculesSignal 1 and Signal 2 moleculesCostimulatory receptors

Modulation of T-cell activation through the engagement or blockade of antigen-specific and secondary signaling pathways.